Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion

Canadian Journal of Gastroenterology and Hepatology

Volumn 2017, Issue , 2017, Pages

  Cavallaro, Flaminia ^a   Duca, Lorena ^b,c   Pisani, Laura Francesca ^a   Rigolini, Roberta ^a   Spina, Luisa ^a   Tontini, Gian Eugenio ^a   Munizio, Nadia ^a   Costa, Elena ^a   Cappellini, Maria Domenica ^b,c   Vecchi, Maurizio ^a,d   Pastorelli, Luca ^a,d  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ERYTHROFERRONE; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HORMONE; INFLIXIMAB; INTERLEUKIN 6; PROHEPCIDIN; TRANSFERRIN; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; EPO PROTEIN, HUMAN; FAM132B PROTEIN, HUMAN; HEPCIDIN; IL6 PROTEIN, HUMAN; IRON; PEPTIDE HORMONE; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; ANEMIA; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CONTINUOUS INFUSION; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMEOSTASIS; HUMAN; INFLAMMATORY BOWEL DISEASE; IRON METABOLISM; MALE; MIDDLE AGED; PRIORITY JOURNAL; ULCERATIVE COLITIS; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; CHRONIC DISEASE; COLITIS, ULCERATIVE; COMPLICATION; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; ANEMIA; C-REACTIVE PROTEIN; CHRONIC DISEASE; COLITIS, ULCERATIVE; CROHN DISEASE; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMOGLOBINS; HEPCIDINS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; INTERLEUKIN-6; IRON; MALE; MIDDLE AGED; PEPTIDE HORMONES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 85011556972     PISSN: 22912789     EISSN: 22912797     Source Type: Journal    
DOI: 10.1155/2017/6843976     Document Type: Article

References (34)

1. S. Kulnigg and C. Gasche, "Systematic review: managing anaemia in Crohn's disease," Alimentary Pharmacology andTherapeutics, vol. 24, no. 11-12, pp. 1507-1523, 2006.
2. G.Weiss and C.Gasche, "Pathogenesis and treatment of anemia in inflammatory bowel disease," Haematologica, vol. 95, no. 2, pp. 175-178, 2010.
3. G. Semrin, D. S. Fishman, A. Bousvaros et al., "Impaired intestinal ironabsorption inCrohn'sdisease correlateswithdisease activity and markers of inflammation," Inflammatory Bowel Diseases, vol. 12, no. 12, pp. 1101-1106, 2006.
4. J. A. M. Chulilla, M. S. R. Colás, and M. G. Martín, "Classification of anemia for gastroenterologists," World Journal of Gastroenterology, vol. 15, no. 37, pp. 4627-4637, 2009.
5. T. Ganz, "Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation," Blood, vol. 102, no. 3, pp. 783-788, 2003.
6. L. Kautz, G. Jung, E. V. Valore, S. Rivella, E. Nemeth, and T. Ganz, "Identification of erythroferrone as an erythroid regulator of iron metabolism," Nature Genetics, vol. 46, no. 7, pp. 678-684, 2014.
7. E. F. Stange, S. P. L. Travis, S. Vermeire et al., "European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis," Journal of Crohn's &Colitis, vol. 2, no. 1, pp. 1-23, 2008.
8. E. F. Stange,S.P.L.Travis, S. Vermeire et al., "Europeanevidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis," Gut, vol. 55, no. 1, pp. i1-i15, 2006.
9. R. F. Harvey and J. M. Bradshaw, "A simple index of Crohn'sdisease activity," The Lancet, vol. 315, no. 8167, p. 514, 1980.
10. K. W. Schroeder, W. J. Tremaine, and D. M. Ilstrup, "Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study," The New England Journal of Medicine, vol. 317, no. 26, pp. 1625-1629, 1987.
11. E. Costa, D. W. Swinkels, C. M. Laarakkers et al., "Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients," Acta Haematologica, vol. 122, no. 4, pp. 226-229, 2009.
12. G. Dallalio, T. Fleury, and R. T. Means Jr., "Serum hepcidin in clinical specimens," British Journal of Haematology, vol. 122, no. 6, pp. 996-1000, 2003.
13. C. Gasche, M. C. E. Lomer, I. Cavill, and G. Weiss, "Iron, anaemia, and inflammatory bowel diseases," Gut, vol. 53, no. 8, pp. 1190-1197, 2004.
14. L. T. Goodnough and A. R. Nissenson, "Anemia and its clinical consequences in patients with chronic diseases," The American Journal of Medicine, vol. 116, supplement 7, pp. 1S-2S, 2004.
15. L. T. Pizzi, C.M.Weston,N. I.Goldfarbet al., "Impact of chronic conditions on quality of life in patients with inflammatory bowel disease," Inflammatory Bowel Diseases, vol. 12, no. 1, pp. 47-52, 2006.
16. C. Leitgeb, M. Pecherstorfer, E. Fritz, and H. Ludwig, "Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin," Cancer, vol. 73, no. 10, pp. 2535-2542, 1994.
17. P. Oustamanolakis, I. E. Koutroubakis, I. Messaritakis, N. Malliaraki, A. Sfiridaki, and E. A. Kouroumalis, "Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease," European Journal of Gastroenterology and Hepatology, vol. 23, no. 3, pp. 262-268, 2011.
18. J. Nagy, L. Lakner, V. S. Poór et al., "Serum prohepcidin levels in chronic inflammatory bowel diseases," Journal of Crohn's & Colitis, vol. 4, no. 6, pp. 649-653, 2010.
19. J.Arnold, A. Sangwaiya, B. Bhatkal, F. Geoghegan, andM. Busbridge, "Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis," European Journal of Gastroenterology&Hepatology, vol. 21,no. 4, pp. 425-429, 2009.
20. R. J. Basseri, E. Nemeth,M. E. Vassilaki et al., "Hepcidin is a key mediator of anemia of inflammation in Crohn's disease," Journal of Crohn's and Colitis, vol. 7, no. 8, pp. e286-e291, 2013.
21. I. Theurl, E. Aigner, M.Theurl et al., "Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications," Blood, vol. 113, no. 21, pp. 5277-5286, 2009.
22. G. Bergamaschi, A. D. Sabatino, R. Albertini et al., "Serum hepcidin in inflammatory bowel diseases: biological and clinical significance," Inflammatory Bowel Diseases, vol. 19, no. 10, pp. 2166-2172, 2013.
23. Z. B. Paköz, C. Çekiç, M. Arabul et al., "An evaluation of the correlation between hepcidin serum levels and disease activity in inflammatory bowel disease," Gastroenterology Research and Practice, vol. 2015, Article ID 810942, 4 pages, 2015.
24. G. Bergamaschi, A. Di Sabatino, R. Albertini et al., "Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-α treatment," Haematologica, vol. 95, no. 2, pp. 199-205, 2010.
25. D. Davis, P. J. Charles, A. Potter, M. Feldmann, R. N. Maini, and M. J. Elliott, "Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor α blockade," British Journal of Rheumatology, vol. 36, no. 9, pp. 950-956, 1997.
26. C. Bes, A. Yazici, and M. Soy, "Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis," Rheumatology International, vol. 33,no. 6, pp. 1415-1418, 2013.
27. N. K. N. Shanmugam, E. Trebicka, L.-L. Fu, H. N. Shi, and B. J. Cherayil, "Intestinal inflammation modulates expression of the iron-regulating hormone hepcidin depending on erythropoietic activity and the commensal microbiota," The Journal of Immunology, vol. 193, no. 3, pp. 1398-1407, 2014.
28. E. Nemeth, S. Rivera, V. Gabayan et al., "IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin," The Journal of Clinical Investigation, vol. 113, no. 9, pp. 1271-1276, 2004.
29. P. Charles, M. J. Elliott, D. Davis et al., "Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis," Journal of Immunology, vol. 163, no. 3, pp. 1521-1528, 1999.
30. M. J. Elliott, P.Woo, P.Charles, A. Long-Fox, J.N.Woody, and R. N.Maini, "Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated withmonoclonal antibody to tumour necrosis factor-α (cA2)," British Journal of Rheumatology, vol. 36, no. 5, pp. 589-593, 1997.
31. J. Brandt, H. Haibel, D. Cornely et al., "Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab," Arthritis & Rheumatism, vol. 43, no. 6, pp. 1346-1352, 2000.
32. P. Emery, R. M. Fleischmann, L. W. Moreland et al., "Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twentyfour-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis," Arthritis and Rheumatism, vol. 60, no. 8, pp. 2272-2283, 2009.
33. L. Kautz, G. Jung, E. Nemeth, and T. Ganz, "Erythroferrone contributes to recovery from anemia of inflammation," Blood, vol. 124, no. 16, pp. 2569-2574, 2014.
34. E. Gammella, V. Diaz, S. Recalcati et al., "Erythropoietin's inhibiting impact on hepcidin expression occurs indirectly," American Journal of Physiology - Regulatory Integrative and Comparative Physiology, vol. 308, no. 4, pp. R330-R335, 2015.